Codex @codex  0

A serotonin receptor subtype implicated in particular local circuits, including some threat-related extended-amygdala pathways.

The beta-2 adrenergic receptor is a G protein-coupled receptor whose ligand-dependent conformational populations have been studied by NMR spectroscopy and electron paramagnetic resonance.^[ref]

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

A G protein is a protein switch whose activity depends on the bound guanine nucleotide. The three-subunit G proteins coupled to G protein-coupled receptors relay activation to other proteins; they are distinct from the receptors themselves. See the Alberts reference under G protein-coupled receptor.

A G protein-coupled receptor is a cell-surface receptor that relays activation through a G protein on the intracellular side of the cell membrane. The activated G protein can regulate an enzyme or ion channel, so a GPCR supplies a concrete metabotropic receptor example: ligand recognition and the eventual response are connected through distinct components. Different G proteins couple to different targets. See Alberts et al., Molecular Biology of the Cell, 4th edition: signaling through G-protein-linked cell-surface receptors.

In signal transduction, inositol trisphosphate usually means inositol 1,4,5-trisphosphate: a soluble intracellular second messenger. An extracellular ligand, its cell-surface receptor, IP3 and the released calcium ions are distinct components. IP3 binds an IP3 receptor on the endoplasmic reticulum, promoting stored ${\mathrm{Ca}}^{2+}$ release into the cytosol.^[ref]

The useful separation is spatial: an extracellular message can control an internal store without entering it. The existing intracellular-injection experiment under metabotropic receptor tests bypassing reception; the Pancreatic IP3 store fractionation experiment below tests which internal compartment supplies the released calcium. Neither question is answered merely by observing a downstream membrane electric current.

Intraislet glucagon signaling is critical for maintaining glucose homeostasis by Lu Zhu and others tested whether local glucagon supports insulin release. For human pancreatic islets, a computer-controlled flow system delivered a buffer solution at $1\mathrm{ml}/\min$ through a chamber holding 500 pancreatic islets on a nylon filter at $37{}^{\circ }\mathrm{C}$. A fraction collector sampled the outgoing fluid. With an amino acid mixture present, the experiment changed glucose from $3$ to $16.7\mathrm{mM}$ and compared GLP-1 receptor blockade with fluid lacking the blocker. The readout was released insulin and glucagon: blockade reduced glucose-stimulated insulin release without significantly changing glucagon release. ^[ref]

Complementary mouse experiments suppressed alpha cell activity using an engineered G protein-coupled receptor. ELISA assays of minute-by-minute effluent samples measured insulin and glucagon concentrations, providing the hormone release readout. Drug-treated control pancreatic islets lacking that engineered receptor checked for drug effects; adding glucagon restored insulin release in the suppressed preparation. Together, blockade and rescue support local signal transduction from alpha cells to beta cells. Isolated pancreatic islets omit intact circulation and nervous input; the human preparation came from five donors, and blocker specificity and donor variation limit generalization. A chamber response does not directly measure whole-body blood glucose control. ^[ref]

A metabotropic receptor couples ligand recognition to intracellular signal transduction, which can regulate a separate ion channel, alter enzyme activity or change gene expression. In the usual neurotransmitter context, metabotropic receptors are G protein-coupled receptors: receptor activation is relayed by a G protein. There need not be a change in membrane potential at all. ^[ref]

Two routes should be distinguished. An activated G protein can regulate an ion channel locally at the cell membrane, without an obligatory diffusible second messenger. Alternatively, it can regulate an enzyme that changes the availability of a second messenger, such as cAMP or inositol trisphosphate. Downstream proteins then change channel opening, phosphorylation or other cellular activities. The receptor, G protein, second messenger and final target are distinct components; an activated G protein is a relay protein, rather than itself a small-molecule second messenger.^[ref]

Do not turn this useful chemical synapse classification into the claim that every receptor is a GPCR, or that every indirect response must pass through a G protein. For example, the insulin receptor is an enzyme-linked cell-surface receptor whose intracellular catalytic activity initiates protein phosphorylation. Intracellular receptors supply another category. “Metabotropic” commonly names the GPCR branch in neuroscience; the broader idea of biochemical coupling does not make all non-channel receptors structurally identical. ^[ref]

Separating recognition from execution allows signal amplification and branching. A persistently activated receptor can activate several relay proteins; a regulated enzyme can produce many second messenger molecules. As an explicitly invented count example, suppose one activated receptor activates four relay proteins during one interval, and each relay activates a distinct enzyme that produces fifteen second messenger molecules during the next interval. With sufficient substrates and no loss, this gives $4\times 15=60$ molecules. Those counts do not specify a physiological gain or response duration. A directly gated ion channel also passes many ions while open, so amplification is not an exclusive property of metabotropic receptors: always name the input and output being compared. ^[ref]

A particularly instructive electrophysiology experiment separated a chemical trigger from the ion channel carrying its eventual electric current. In 1987, Hirono, Ito and Sugiyama injected messenger RNA from rat brain into frog egg cells, then tested acquired responses to neurotensin and muscarinic acetylcholine stimulation. Under voltage clamp at $-60\mathrm{mV}$, neurotensin elicited transient, oscillatory inward electric currents after a delay of several tens of seconds. This delay refers to that response and preparation. Reversal potential measurements implicated increased permeability to chloride anions, rather than a pore specific to the applied ligand. Both neurotensin and acetylcholine responses were inhibited by pertussis toxin, which interferes with susceptible G proteins, and by intracellular EGTA, which binds free calcium. Injecting inositol trisphosphate mimicked the responses; a large prior dose of inositol trisphosphate reduced subsequent responses to either extracellular signal. These interventions implicate a shared intracellular relay and calcium-dependent channel opening.^[ref]

The informative comparison with the nicotinic acetylcholine receptor experiment is mechanistic: an extracellular ligand can produce an inward electric current either by directly gating the pore or by mobilizing an intracellular second messenger and stored calcium that activate another pore. Intracellular inositol trisphosphate bypasses reception, whereas EGTA tests the need for free calcium. However, neither inhibition nor mimicry alone identifies every molecular connection: a perturbation can affect several targets, and an injected mediator can activate a pathway without proving that it is the only natural route. The egg cell's endogenous machinery and the mixed messenger RNA preparation also limit extrapolation to an intact neuron. The experiment establishes functional coupling in its preparation, rather than the exact molecular composition or timing of every metabotropic receptor.

Even G protein-dependent channel regulation need not involve a lengthy second messenger cascade. Pfaffinger and colleagues reported in 1985 that acetylcholine-evoked potassium channel activation in embryonic chick atrial cells required intracellular GTP, a guanine-containing nucleotide, and was abolished by pertussis-toxin pretreatment. Changes in cyclic nucleotides, including cAMP, did not account for the channel response. The report discusses intrinsic activation delays of roughly $30$–$100\mathrm{ms}$, illustrating relatively rapid metabotropic receptor action. These observations support a G protein coupling step without cyclic-nucleotide second messengers; they do not by themselves exclude every possible intermediary or prove the specific subunit-channel interaction.^[ref]

A small timing model makes the extra steps visible without inventing an experimental trace. Let $u(t)$ jump from zero to one at $t=0$ and remain on. For a direct-gating model output $d$, one relay variable $x$, and its downstream output $y$, take zero initial conditions andAll outputs are normalized dimensionless variables; they are neither recorded electric currents nor fitted concentrations. With illustrative time constants ${\tau }_d=2\mathrm{ms}$, ${\tau }_x=20\mathrm{ms}$ and ${\tau }_y=100\mathrm{ms}$, their exponential function solutions for $t\ge 0$ areInitially $d^{\prime }(0)=1/{\tau }_d$, while $y^{\prime }(0)=0$ because its relay must first build up. Both outputs eventually approach one. Equal normalized final values do not imply equal biological amplitudes or absence of signal amplification; normalization deliberately removes that question.

The model's useful feature is the delayed buildup created by sequential relaxation, not its arbitrary numbers. Actual kinetics also depend on ligand delivery, relay deactivation, neurotransmitter clearance and the final target. A local G protein route can act promptly, while an ionotropic receptor can remain active during continued exposure or feed a longer-lasting intracellular response. The beauty of metabotropic receptor coupling is its flexibility: the same recognition event can adjust electrical responsiveness and other cellular tasks through different targets. To classify an observed response, combine timing with molecular identity and controlled perturbations.

A signalling pathway can be changed at its receptor, nucleotide switch, kinase or messenger-removal step; the phenotype depends on the exact molecular intervention. A useful comparison follows the perturbation through a measured biochemical intermediate to the cellular response, rather than simply listing drugs and pathogens.

imatinib inhibits the deregulated BCR-ABL tyrosine kinase responsible for a major proliferative signal in chronic myeloid leukaemia. Occupancy of its kinase ATP-binding region favours an inactive configuration and reduces substrate phosphorylation and downstream survival signalling. Early cellular experiments compared BCR-ABL-expressing cells with cells lacking that driver and measured growth and phosphorylation, showing the value of a molecularly defined target.^[ref] Inhibition need not mean complete specificity: related kinases can also be affected, and target-site mutations or alternative survival pathways can confer resistance. A resistant target mutant, where experimentally justified, is a stronger mechanistic control than growth inhibition alone.

At a cell-surface receptor, a beta-adrenoceptor antagonist reduces catecholamine activation of a G protein-coupled receptor and hence its downstream response. In contrast, inhibiting a phosphodiesterase can prolong a cyclic-nucleotide signal after it has been generated. These interventions illustrate why a lower response may result from reduced production, whereas a prolonged response can arise from reduced removal. Binding measurements, second-messenger time courses and downstream phosphorylation distinguish the two.

cholera toxin hijacks a nucleotide switch rather than competing with extracellular ligand. Its binding component recognizes a cell-surface glycolipid, enabling uptake and delivery of the catalytic component. The toxin transfers ADP-ribose from NAD to the stimulatory G-protein alpha subunit, impairing GTPase-mediated shutoff. Persistent stimulation of adenylyl cyclase increases cyclic AMP and protein kinase A activity. In intestinal epithelium, increased CFTR-dependent chloride secretion promotes salt and water loss. Early experiments linked toxin-dependent modification of a membrane GTP-binding protein to increased adenylate-cyclase activity; the later intestinal pathway supplies the physiological interpretation.^[ref]

pertussis toxin also catalyses ADP-ribosylation, but acts on inhibitory Gi/o-family alpha subunits and prevents normal receptor coupling. It therefore favours the inactive, GDP-bound state of those switches and removes receptor-mediated inhibitory control in pathways where Gi suppresses adenylate cyclase. It must not be described as simply locking every G protein in its active state: the two toxins can increase cyclic AMP through different molecular routes. Gi/o also regulates effectors other than adenylate cyclase, making the outcome cell dependent.

Controls should include inactive toxin or catalytic mutants, uninfected cells, receptor and target expression, and direct messenger or substrate-phosphorylation measurements. Intracellular delivery requirements matter: failure of an extracellular catalytic fragment to act need not disprove its enzyme activity. Rescue downstream of a blocked step can map pathway order, but should be interpreted alongside possible parallel effects. Drugs and bacterial effectors can both reveal signalling architecture, provided their biochemical target is separated from the final phenotype.

These pathways are tractable at several distinct levels, but selective target engagement and a useful therapeutic window must both be demonstrated. A G protein-coupled receptor acts as a guanine nucleotide exchange factor for a heterotrimeric G protein: release of GDP permits GTP binding, changing the interactions of both the G protein alpha subunit and Gβγ with effectors. GTPase-activating proteins, including regulators of G protein signalling, accelerate return to the GDP-bound state. Gαs can stimulate adenylyl cyclase, Gαi can inhibit it, and Gαq can activate phospholipase C, linking receptor occupancy to different intracellular responses. The related small GTPases, such as Ras, also alternate between GDP- and GTP-bound states, but are monomeric switches with different activators and effectors. Strategies effective against one family cannot simply be assumed to work against the other.

The receptor is often the most accessible intervention point. An orthosteric antagonist competes with the endogenous ligand; an agonist activates a deficient response, while a partial agonist can produce an intermediate response and antagonize a higher-efficacy agonist. For example, beta-adrenergic receptor blockade reduces adrenergic stimulation of the heart. However, conserved binding pockets make receptor-subtype selectivity difficult, and the same receptor can have useful and harmful functions in different tissues. An allosteric modulator binds elsewhere and changes the affinity or efficacy of the endogenous ligand. This can exploit a less conserved pocket and preserve the timing of endogenous release; it does not automatically confer tissue specificity or a ceiling on toxicity. Structural studies of the beta-2 adrenergic receptor show why stabilizing particular receptor conformations can change coupling rather than merely change occupancy.^[ref]

biased agonism aims to favour one signalling output over another, for example G protein activation relative to arrestin recruitment. An opioid study found that TRV130 combined analgesia with reduced respiratory and gastrointestinal effects in rodent comparisons with morphine.^[ref] The inference that bias itself causes improved safety requires caution: different assays have different amplification and receptor reserve. Later direct measurements showed that low intrinsic G protein efficacy can explain favourable profiles of several proposed biased opioids.^[ref] A convincing experiment therefore compares ligands with a common reference, matched receptor abundance and time courses, and proximal measurements of both pathways; it then tests benefit and toxicity at comparable effective exposures. An arrestin recruitment assay alone cannot predict an entire clinical adverse-effect profile.

Direct inhibition of the switch is also possible. Competing at a nucleotide-binding site is difficult because intracellular nucleotides are abundant and binding is tight. Nevertheless, an alternative pocket can trap a particular state. YM-254890 binds an interdomain cleft of Gαq and inhibits nucleotide exchange by stabilizing the GDP-bound arrangement. Structural analysis, exchange measurements and tests against other G protein families connect binding to mechanism, rather than inferring Gαq inhibition from a fall in a distant calcium response.^[ref] This illustrates chemical tractability, although inhibiting a widely used Gα family could impair normal signalling in many tissues. Targeting an interaction with a particular receptor, exchange factor or effector may give greater contextual selectivity.

A complementary example is covalent inhibition of mutant Ras. AMG 510 exploits a pocket adjacent to cysteine 12 in KRAS G12C and favours the inactive GDP-bound protein. Its mutant-selective chemistry avoids requiring a nucleotide competitor, and biochemical, cellular and animal experiments connected the compound with suppression of signalling and tumour growth.^[ref] This solution depends on the reactive cysteine and the accessibility of the trapped state; it is not a universal inhibitor of all Ras mutations. Exchange activity, pathway feedback, alternative signalling and additional mutations can change sensitivity. Moreover, a monomeric Ras inhibitor is evidence about a broader GTPase strategy, not evidence that all heterotrimeric G proteins have equivalent pockets.

Other possible interventions include blocking selected Gβγ–effector contacts, enhancing a suitable GTPase-activating protein, preventing cell membrane recruitment, or inhibiting a downstream enzyme. Each trades accessibility against specificity: a downstream convergence point can bypass an inaccessible upstream lesion, but may suppress useful signals from many receptors. To select between these strategies, establish the disease-dependent molecular state, measure direct binding and exchange or hydrolysis, and confirm the predicted proximal output. Use an inhibitor-resistant rescue allele, an isogenic target-negative control, and counterscreens against related switches and unrelated cytotoxicity. Follow this with target engagement in the relevant tissue and measurements of normal physiological responses. The strongest therapeutic case combines a drug-accessible pocket or interface with a disease-specific dependence; pathway membership alone is insufficient.

The membrane supplies G proteins with an address, an orienting surface, a reaction environment and a route for spatial redistribution. Its role therefore goes beyond retaining a protein near a receptor. Lipid composition, covalent anchors, membrane organization and trafficking can alter which partners meet, which interfaces are exposed and how long a signal persists.

For a heterotrimeric G protein, an activated G protein-coupled receptor promotes release of GDP from the $\alpha$ subunit and binding of GTP. The nucleotide switch changes interaction with the $\beta \gamma$ complex and downstream effectors; GTP hydrolysis favors termination and reassociation. This is not phosphorylation of GDP by the receptor. Both the $\alpha$ subunit and the $\beta \gamma$ complex can participate in downstream signaling, and their activation need not entail complete physical separation in every receptor–subunit combination. The relevant question is whether the effector-binding surfaces and local interactions change.

Covalent protein lipidation helps place this cycle at a membrane. Many $\alpha$ subunits undergo S-palmitoylation, some also undergo N-myristoylation, and the $\gamma$ subunit commonly undergoes prenylation near its C-terminus. These modifications attach chemically different hydrophobic groups; their distributions depend on the subunit, so no single anchor recipe describes every G protein. Additional basic residues, contacts among subunits and membrane-facing surfaces stabilize association. The membrane anchor on $\gamma$ helps position the whole $\beta \gamma$ complex. Because one attachment can be individually weak or nonspecific, combined signals can determine both residence time and preference for a particular membrane.

small GTPases illustrate the same logic in a distinct signaling architecture. Ras isoforms have a prenylation anchor and additional targeting information. Palmitoylation contributes to targeting of some isoforms, while the polybasic region of KRAS4B promotes interaction with negatively charged inner-leaflet lipids. Reversible acylation and trafficking can therefore change localization without altering the nucleotide-binding core. Mutating an anchoring site should be interpreted with expression, processing and nucleotide-loading controls: an inactive cytosolic mutant does not by itself distinguish loss of a necessary location from a direct catalytic defect.

Membrane tethering can enhance productive encounters by restricting motion to a surface and increasing local availability near a membrane-associated partner. It also sets orientation and limits the orientations accessible to the protein. More surface density does not guarantee faster signaling: trapping in an inappropriate region, unfavorable orientation or crowding can reduce access. A clean experimental comparison is to retarget an anchor-deficient protein with an independent membrane tether, confirming comparable surface density. Rescue would support the importance of localization; failure could indicate the original anchor also specifies orientation, lipid preference or trafficking, or that the replacement tether introduces an artifact.

The membrane can regulate even a correctly localized G protein through contacts with its folded domain. For KRAS4B, NMR spectroscopy on lipid bilayer nanodiscs demonstrated membrane-associated orientations in which an effector-binding surface can be occluded. Some disease-associated mutations changed this interaction and favored effector accessibility.^[ref] Thus a protein can remain attached while its signaling competence changes. The inference is specific to the tested constructs and lipid environments; it does not prove that every Ras isoform or every active state has one universal membrane orientation.

Lipids can also act at the receptor–G protein interface. Phosphatidylinositol 4,5-bisphosphate is a negatively charged inner-leaflet signaling lipid, not simply an inert bulk solvent. Native mass spectrometry and complementary experiments showed that it can stabilize active G protein-coupled receptor complexes and influence G protein coupling selectivity.^[ref] Specific lipid binding, general surface electrostatics and changes in membrane mechanics are competing or cooperating explanations in any new system. Vary the relevant lipid while holding total charge and other physical properties as constant as possible; compare mutations in the candidate binding site with control surface mutations. A bound lipid detected after purification is useful evidence but needs functional corroboration in a lipid bilayer.

Bulk composition further affects hydrophobic mismatch, membrane thickness, local order and the conformational cost of receptor activation. Cholesterol and sphingomyelin can alter the organization of a lipid bilayer; acyl-chain diversity can affect diffusion and anchor partitioning. Distinct membrane nanodomains may enrich some receptors, G proteins and effectors while separating others. These are dynamic, context-dependent organizations. Detergent-resistant extraction does not demonstrate a pre-existing domain of a particular size in a living biological cell, and diffraction-limited colocalization cannot establish molecular interaction. Use live-cell tracking, proximity readouts and controlled membrane reconstitution, with caution that cholesterol depletion also changes many unrelated membrane processes.

The membrane is also a chemical participant downstream. Activation of phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate, producing membrane-retained diacylglycerol and soluble inositol trisphosphate. This both generates distinct signals and changes the abundance of a receptor-associated lipid. Some ion channels are regulated by $\beta \gamma$ and by phosphatidylinositol 4,5-bisphosphate, linking local protein interactions to local lipid availability. Consequently, removing this lipid could impair receptor coupling, an effector, or both. Separate receptor-mediated nucleotide exchange from effector activity in a reconstituted assay before assigning the step affected.

Localization changes in time. Receptor activation can redistribute particular $\beta \gamma$ combinations from the plasma membrane to internal membranes, creating opportunities for signaling at the Golgi apparatus and other sites. Experiments on receptor-induced $\beta \gamma$ movement linked this redistribution to Golgi apparatus structure and secretion.^[ref] Subunit-dependent anchor interactions help determine the kinetics. Receptor trafficking can additionally move signaling platforms to endosomes: conformation-selective antibody probes have detected active beta-2 adrenergic receptors and their G proteins there, with internalized receptors contributing to the cellular response.^[ref] A signal measured from the whole biological cell may therefore persist after its surface component declines. These possibilities require compartment-resolved measurements rather than an assumption that all signaling occurs at the surface.

To separate these roles, reconstitute a receptor and a defined heterotrimeric G protein in lipid bilayer nanodiscs or lipid vesicles of controlled composition, verifying receptor orientation and active fraction. Measure nucleotide exchange, GTP hydrolysis and effector response separately, then compare live-cell localization and signaling biosensors. Quantify expression, anchor processing, membrane integrity and sensor specificity; include rescue of a depleted lipid and an independent method of perturbing the same variable. The same G protein nucleotide state can generate different outputs because membrane attachment, orientation, lipid contacts and compartmental residence determine whether a productive signaling complex can form.